Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Back pain, Bladder pain, COVID-19, Inappropriate schedule of product administration, Lymphocyte count
Clinical narrative: he contracted Covid twice after being vaccinated; got bladder pains; weird back pains; Patient was vaccinated in 2020, date is uncertain. He had a second shot late 2021; type 1 diabetes/disoriented/illness; This spontaneous case was reported by a patient and describes the occurrence of TYPE 1 DIABETES MELLITUS (type 1 diabetes/disoriented/illness) in a 26-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. ASKU and ASKU) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   In 2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2022, the patient experienced TYPE 1 DIABETES MELLITUS (type 1 diabetes/disoriented/illness) (seriousness criterion medically significant). On an unknown date, the patient experienced COVID-19 (he contracted Covid twice after being vaccinated), BLADDER PAIN (got bladder pains), BACK PAIN (weird back pains) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient was vaccinated in 2020, date is uncertain. He had a second shot late 2021). At the time of the report, TYPE 1 DIABETES MELLITUS (type 1 diabetes/disoriented/illness) and COVID-19 (he contracted Covid twice after being vaccinated) had not resolved and BLADDER PAIN (got bladder pains), BACK PAIN (weird back pains) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient was vaccinated in 2020, date is uncertain. He had a second shot late 2021) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Lymphocyte count: low pancreatic T-cell count. On an unknown date, SARS-CoV-2 test: Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication not reported.   Treatment medication not reported.  The patient developed type 1 diabetes after receiving second dose of vaccine had low T-cells amount lost 40 pounds. The patient was relatively healthy young individual. He was active and not overweight; he had never had a bad check up. He had never any serious health complications. There was no family history of type one diabetes in my family. He had been a little skeptical to vaccinate against Covid-19 and he finally did get two shots of the Moderna vaccine, he was a relatively healthy young individual. he worked out, he went for walks, he went outside. He had active, he was not overweight, he had a fit, healthy, young individual. At the time when he contracted this illness, he was working a job where he was on his feet eight hours a day. He had never had a bad check up. He had never had any serious health complications. Over the course of a few months last year, he lost about 40lb out of nowhere. He could not, stay hydrated, got bladder pains, weird back pains, was completely, just disoriented, out of energy. Had no idea what was going on for months. He could not figure it out and, he went and got some blood work done and it turns out, his T cells, his pancreas T cells were super low. They told him he had contracted type one diabetes. And, he knew, there were no family history of type one diabetes in his family.  Company Comment: This is a spontaneous case concerning a 26-year-old male patient, who experienced an unexpected serious (medically significant) event of type 1 diabetes. The patient, a previously healthy and active young individual without a history of serious health issues or a family history of type 1 diabetes, developed type 1 diabetes after receiving the second dose of the mRNA-1273 vaccine. The latency is unknown. He experienced significant weight loss of 40 pounds, dehydration, bladder and back pains, and disorientation. The first and second doses were administered with an interval longer than expected. It is also reported that the patient experienced COVID-19 twice after the second dose. No further information on the clinical course, investigations, and treatment received was available in the report. The benefit-risk relationship of the mRNA-1273 Vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 08-Apr-2024: New events (COVID-19, illness, bladder pain, back pain, disorientated and inappropriate schedule of vaccine administered) and lab test added. On 08-Apr-2024: The seriousness for event COVID-19 updated to disability. On 08-Apr-2024: FU3: Reporter details added, the outcome of event COVID-19 updated from unknown to not recovered and lab test added. The event onset date for Diabetes mellitus added and narrative updated. On 08-Apr-2024: Live significant follow up added. LRN were added. On 09-Apr-2024: Live-non-significant follow-up received. On 10-Apr-2024: Live-non-significant follow-up received. On 12-Apr-2024: Live-non-significant follow-up received.; Sender's Comments: This is a spontaneous case concerning a 26-year-old male patient, who experienced an unexpected serious (medically significant) event of type 1 diabetes. The patient, a previously healthy and active young individual without a history of serious health issues or a family history of type 1 diabetes, developed type 1 diabetes after receiving the second dose of the mRNA-1273 vaccine. The latency is unknown. He experienced significant weight loss of 40 pounds, dehydration, bladder and back pains, and disorientation. The first and second doses were administered with an interval longer than expected. It is also reported that the patient experienced COVID-19 twice after the second dose. No further information on the clinical course, investigations, and treatment received was available in the report. The benefit-risk relationship of the mRNA-1273 Vaccine is not affected by this report.